keyword
MENU ▼
Read by QxMD icon Read
search

Venlafaxine and parkinson

keyword
https://www.readbyqxmd.com/read/27073741/repurposing-psychiatric-medicines-to-target-activated-microglia-in-anxious-mild-cognitive-impairment-and-early-parkinson-s-disease
#1
REVIEW
Edward C Lauterbach
Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of neurodegeneration in MCI and early PD via inflammatory mechanisms and the generation of degenerative proinflammatory cytokines. Psychiatric disorders, prevalent in AD and PD, are often treated with psychiatric drugs (psychotropics), raising the question of whether psychotropics might therapeutically affect microglial activation, MCI, and PD...
2016: American Journal of Neurodegenerative Disease
https://www.readbyqxmd.com/read/27063094/drugs-with-potential-cardiac-adverse-effects-retrospective-study-in-a-large-cohort-of-parkinsonian-patients
#2
A Heranval, R Lefaucheur, D Fetter, A Rouillé, F Le Goff, D Maltête
INTRODUCTION/OBJECTIVE: Drugs with potential cardiac adverse effects are commonly prescribed in Parkinson's disease (PD). To describe demographic and clinical characteristics in a group of PD patients with cardiac events and to evaluate risk factors. PATIENTS AND METHODS: We sampled 506 consecutive PD patients (211 women/295 men), median age 68.3±10.6 years (range 36-95) and median disease duration 11.2±6.5 years (range 1-49). Medications with potential cardiac effects, i...
April 2016: Revue Neurologique
https://www.readbyqxmd.com/read/27004670/antidepressants-in-parkinson-s-disease-recommendations-by-the-movement-disorder-study-group-of-the-neurological-association-of-madrid
#3
E Peña, M Mata, L López-Manzanares, M Kurtis, M Eimil, J C Martínez-Castrillo, I Navas, I J Posada, C Prieto, C Ruíz-Huete, L Vela, B Venegas
INTRODUCTION: Although antidepressants are widely used in Parkinson's disease (PD), few well-designed studies to support their efficacy have been conducted. DEVELOPMENT: These clinical guidelines are based on a review of the literature and the results of an AMN movement disorder study group survey. CONCLUSIONS: Evidence suggests that nortriptyline, venlafaxine, paroxetine, and citalopram may be useful in treating depression in PD, although studies on paroxetine and citalopram yield conflicting results...
March 19, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/26996500/beneficial-effect-of-antidepressants-against-rotenone-induced-parkinsonism-like-symptoms-in-rats
#4
Nidhika Sharma, Sumit Jamwal, Puneet Kumar
Parkinson's disease is a second most common age-related neurodegenerative disorder characterized by the loss of DA neurons of SNpc region of the midbrain. Neurotransmitter dysfunction is involved in the pathogenesis of PD. Antidepressants like venlafaxine and sertraline expected to improve Parkinsonism like symptoms by modulating the levels of various neurotransmitters. The neuroprotective role of antidepressants is well explored in various CNS disorders. Therefore, this study was designed to explore and compare the mechanistic role of different antidepressants (venlafaxine and sertraline) against rotenone induced Parkinsonism like symptoms in rats...
June 2016: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://www.readbyqxmd.com/read/26423182/efficacy-safety-and-tolerability-of-augmentation-pharmacotherapy-with-aripiprazole-for-treatment-resistant-depression-in-late-life-a-randomised-double-blind-placebo-controlled-trial
#5
RANDOMIZED CONTROLLED TRIAL
Eric J Lenze, Benoit H Mulsant, Daniel M Blumberger, Jordan F Karp, John W Newcomer, Stewart J Anderson, Mary Amanda Dew, Meryl A Butters, Jacqueline A Stack, Amy E Begley, Charles F Reynolds
BACKGROUND: Treatment-resistant major depression is common and potentially life-threatening in elderly people, in whom little is known about the benefits and risks of augmentation pharmacotherapy. We aimed to assess whether aripiprazole is associated with a higher probability of remission than is placebo. METHODS: We did a randomised, double-blind, placebo-controlled trial at three centres in the USA and Canada to test the efficacy and safety of aripiprazole augmentation for adults aged older than 60 years with treatment-resistant depression (Montgomery Asberg Depression Rating Scale [MADRS] score of ≥15)...
December 12, 2015: Lancet
https://www.readbyqxmd.com/read/24679737/severity-of-depression-and-anxiety-are-predictors-of-response-to-antidepressant-treatment-in-parkinson-s-disease
#6
A J H Moonen, A Wijers, A F G Leentjens, C W Christine, S A Factor, J Juncos, J M Lyness, L Marsh, M Panisset, R Pfeiffer, D Rottenberg, C Serrano Ramos, L Shulman, C Singer, J Slevin, W McDonald, P Auinger, I H Richard
BACKGROUND: Antidepressants have appeared to be more effective than placebo treatment in treating depressive syndromes in patients with Parkinson's disease (PD). OBJECTIVE: To identify factors that predict improvement in depressive symptoms during antidepressant treatment in depressed PD patients. METHODS: A secondary analysis was performed on the dataset of the Randomized Placebo-controlled Study of Antidepressants in PD (SAD-PD), in which 76 patients received active treatment with either paroxetine or venlafaxine extended release (XR), and 39 patients received placebo treatment...
June 2014: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/24532378/anxiety-and-depression-in-parkinson-s-disease
#7
Atbin Djamshidian, Joseph H Friedman
Anxiety and depression, while very common problems in Parkinson's disease (PD), have not been subject to adequate treatment trials. While a handful of double blind placebo-controlled trials of depression have been published, only a small number of subjects have been enrolled in most of these. There have been no adequate treatment trials of anxiety. Thus, most practitioners base their treatments on what has been published in the general population and their own personal experience. The data suggest that depression is probably treatable in some cases, but there are no data to support any drug treatment of anxiety...
April 2014: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/24372461/comparative-assessment-of-adherence-measures-and-resource-use-in-ssri-snri-treated-patients-with-depression-using-second-generation-antipsychotics-or-l-methylfolate-as-adjunctive-therapy
#8
Rolin L Wade, Sylvia L Kindermann, Qingjiang Hou, Michael E Thase
BACKGROUND: Antidepressant monotherapy is effective in achieving treatment remission in only approximately one third of patients with depression, and even switching to a second antidepressant brings the cumulative remission rate to only 50%-55%. This has led to an interest in augmentation therapy for the management of treatment-resistant depression. OBJECTIVES: To assess (a) selective serotonin reuptake inhibitor/selective norepinephrine reuptake inhibitor (SSRI/SNRI) adherence when augmented with second-generation atypical antipsychotics (SGAs) or L-methylfolate using a modified application of the Healthcare Effectiveness Data and Information Set (HEDIS) acute medication management (AMM) measures at the time of augmentation, and (b) the depression-specific and total health care cost, comparing the 2 forms of augmentation therapy in the treatment of depressive disorder...
January 2014: Journal of Managed Care Pharmacy: JMCP
https://www.readbyqxmd.com/read/24201052/antidepressant-like-activity-of-the-adenosine-a-2a-receptor-antagonist-istradefylline-kw-6002-in-the-forced-swim-test-and-the-tail-suspension-test-in-rodents
#9
Koji Yamada, Minoru Kobayashi, Akihisa Mori, Peter Jenner, Tomoyuki Kanda
RATIONALE: Depression is common in Parkinson's disease (PD) but its response to classical antidepressants is not clear. The adenosine A2A antagonist istradefylline is effective in the treatment of the motor symptoms of PD but inhibition of the adenosine A2A receptor may also induce antidepressant-like effects. OBJECTIVE: We have investigated whether istradefylline might be effective in treating depression in PD using the forced swimming test (FST) and the tail suspension test (TST) in rodents...
December 2013: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/23896940/effect-of-diclofenac-and-antidepressants-on-the-inflammatory-response-in-astrocyte-cell-culture
#10
COMPARATIVE STUDY
Md Mamun Al-Amin, Mir Muhammad Nasir Uddin, Md Mahbubur Rahman, Hasan Mahmud Reza, Md Sohel Rana
Central nervous system (CNS) has a completely separate immune system that communicates with the neurons by small molecules called cytokines. Cytokines are involved in many crucial processes in neuron including cell metabolism and neurotransmitter synthesis. It has been reported that cytokine imbalance is involved in the progression of many CNS diseases such as neuropsychiatric disorders (depression, schizophrenia, autism, and bipolar disorder) and neurodegenerative disorders (Parkinson's and Alzheimer's disease)...
December 2013: Inflammopharmacology
https://www.readbyqxmd.com/read/23346517/successful-use-of-rasagiline-in-combination-with-two-antidepressants-a-case-report
#11
Narpinder Kaur, Rohit Madan, Ashish Sharma
Parkinson's disease is the second most common neurodegenerative disorder, affecting 1 to 2 percent of people older than 60 years. Recent reviews show that depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 40 to 50 percent of patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Pharmacotherapy for depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions...
November 2012: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/22899034/depression-in-parkinson-s-disease-diagnosis-and-treatment
#12
REVIEW
Flavio Henrique de Rezende Costa, Ana Lucia Zuma Rosso, Henryk Maultasch, Denise Hack Nicaretta, Maurice Borges Vincent
The prevalence of non-motor symptoms in Parkinson's disease (PD) is high. Depression varies from 20 to 50% of the PD patients, and is associated with increasing disability. The key characteristics of depression are anhedonia and low mood. The recommended scales for screening purposes are: HAM-D, BDI, HADS, MADRS and GDS. As for measurement of severity: HAM-D, MADRS, BDI and SDS. In cases with mild depression, non-pharmacological intervention is the treatment of choice. In moderate depression, antidepressants are required...
August 2012: Arquivos de Neuro-psiquiatria
https://www.readbyqxmd.com/read/22496199/a-randomized-double-blind-placebo-controlled-trial-of-antidepressants-in-parkinson-disease
#13
RANDOMIZED CONTROLLED TRIAL
I H Richard, M P McDermott, R Kurlan, J M Lyness, P G Como, N Pearson, S A Factor, J Juncos, C Serrano Ramos, M Brodsky, C Manning, L Marsh, L Shulman, H H Fernandez, K J Black, M Panisset, C W Christine, W Jiang, C Singer, S Horn, R Pfeiffer, D Rottenberg, J Slevin, L Elmer, D Press, H C Hyson, W McDonald
OBJECTIVE: To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD). METHODS: A total of 115 subjects with PD were enrolled at 20 sites. Subjects were randomized to receive an SSRI (paroxetine; n = 42), an SNRI (venlafaxine extended release [XR]; n = 34), or placebo (n = 39). Subjects met DSM-IV criteria for a depressive disorder, or operationally defined subsyndromal depression, and scored >12 on the first 17 items of the Hamilton Rating Scale for Depression (HAM-D)...
April 17, 2012: Neurology
https://www.readbyqxmd.com/read/21507731/balance-control-improves-following-replacement-of-paroxetine-with-venlafaxine-and-levodopa-in-a-case-of-microvascular-dementia
#14
Jaime McDonald, Philippe Corbeil, Emmanuelle Pourcher
BACKGROUND: Postural instability is a concern in several neurologic conditions and also among the elderly. Dysfunction in serotonergic, noradrenergic, and dopaminergic pathways may be involved in the etiology of postural imbalance. OBJECTIVE: The objective of this case report was to quantify, using computerized posturography, substitution with venlafaxine, and later levodopa, in a suspected case of postural instability with paroxetine. CASE SUMMARY: Presented is an 86-year-old woman with frequent falls and a Parkinson-like syndrome of the lower limbs secondary to microvascular dementia...
April 2011: American Journal of Geriatric Pharmacotherapy
https://www.readbyqxmd.com/read/20814334/venlafaxine-associated-serotonin-syndrome-causing-severe-rhabdomyolysis-and-acute-renal-failure-in-a-patient-with-idiopathic-parkinson-disease
#15
Senaka Rajapakse, Lakshan Abeynaike, Thanushi Wickramarathne
A 43-year-old male patient with idiopathic Parkinson disease, on dopaminergic therapy, was admitted with confusion and agitation, diaphoresis, and hyperkinesia after the commencement of the serotonin-noradrenaline reuptake inhibitor venlafaxine 2 weeks prior for depression. He was found to have severe rhabdomyolysis and developed acute renal failure. The most likely diagnosis was serotonin syndrome induced by venlafaxine, although neuroleptic malignant syndrome was also considered. The differential diagnosis, atypical features in this presentation, and possible mechanisms are discussed...
October 2010: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/19766953/determinants-of-antidepressant-medication-prescribing-in-elderly-residents-of-aged-care-homes-in-australia-a-retrospective-study
#16
Prasad S Nishtala, Andrew J McLachlan, J Simon Bell, Timothy F Chen
BACKGROUND: Depression is underrecognized and poorly treated among older people living in aged care homes worldwide. Depression has been associated with higher rates of recurrence, disability, and death in older people. OBJECTIVES: The primary objective of this study was to assess the determinants of antidepressant medication prescribing among older people living in aged care homes in Australia. A further objective was to investigate the anti-depressant medications in common use, doses of antidepressants, and concurrent pharmacotherapy among people receiving antidepressants...
August 2009: American Journal of Geriatric Pharmacotherapy
https://www.readbyqxmd.com/read/19695395/systematic-review-and-quality-assessment-of-economic-evaluations-and-quality-of-life-studies-related-to-generalized-anxiety-disorder
#17
REVIEW
Basil G Bereza, Márcio Machado, Thomas R Einarson
BACKGROUND: The objectives of this article were to systematically review, summarize the results of, and assess the quality of economic evaluations and humanistic studies related to patients with generalized anxiety disorder (GAD). METHODS: EMBASE, EBM Reviews, MEDLINE, and HealthSTAR databases were searched (from the time of inception through April 2008). Full-text publications describing full economic evaluations (cost-benefit, cost-minimization, cost-effectiveness, and cost-utility analyses), partial economic evaluations (cost, burden-of-illness, and resource-utilization analyses), and humanistic outcomes (utilities, preferences, and willingness-to-pay analyses) were included...
June 2009: Clinical Therapeutics
https://www.readbyqxmd.com/read/18840035/differences-in-medication-adherence-and-healthcare-resource-utilization-patterns-older-versus-newer-antidepressant-agents-in-patients-with-depression-and-or-anxiety-disorders
#18
David V Sheehan, Matthew S Keene, Michael Eaddy, Stan Krulewicz, John E Kraus, David J Carpenter
BACKGROUND: Given the number of antidepressants available and their rising costs, healthcare payers have initiated restrictive reimbursement policies for newer antidepressants, without consideration for differences in their effectiveness or tolerability. OBJECTIVE: The objective of this study was to comprehensively compare medication adherence rates and associated healthcare utilization costs for patients using later-generation versus earlier-generation antidepressants in a managed care setting...
2008: CNS Drugs
https://www.readbyqxmd.com/read/17187269/-antidepressant-effects-of-dopamine-agonists-experimental-and-clinical-findings
#19
REVIEW
M R Lemke
Results of preclinical and clinical studies implicate that, in addition to serotonin and norepinephrin, dopaminergic mechanisms play a role in the pathogenesis and treatment of depression. Newer antidepressants such as bupropion, sertraline, and venlafaxine act as partial inhibitors of presynaptic dopamine reuptake. Experimental studies show that dopaminergic effects contribute to the development of anxiety, depression, and anhedonia. These studies revealed, among the new nonergot dopamine agonists, anxiolytic properties for ropinirole and anxiolytic, antidepressive, and antianhedonic effects of pramipexole which seem to relate to its specific action on D(2) and D(3) receptors in the mesolimbic system and prefrontal cortex...
January 2007: Der Nervenarzt
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"